Results 311 to 320 of about 4,510,822 (391)
International Forum of Allergy &Rhinology, EarlyView.ABSTRACT Background Chronic rhinosinusitis with nasal polyps (CRSwNP) is a type 2 inflammatory disease often associated with asthma. The global airway hypothesis suggests bidirectional inflammatory interactions between upper and lower airways. Mepolizumab, an anti–IL‐5 therapy, treats conditions systemically, while functional endoscopic sinus surgery ...
Jens Tidemandsen +9 more
wiley +1 more source
International Forum of Allergy &Rhinology, EarlyView.ABSTRACT Background Appropriate medical therapy (AMT) is first‐line treatment for patients with chronic rhinosinusitis (CRS). We evaluated inflammatory structure, treatment‐induced changes, and biomarker‐outcome associations in AMT‐managed patients. Methods Fifty‐one CRS patients were evaluated before and after AMT which included a combination of oral ...
Asher C. Park +9 more
wiley +1 more source
International Forum of Allergy &Rhinology, EarlyView.Key Points Most state Medicaid programs granted omalizumab (91.4%) and dupilumab (59.5%) preferred drug status. Omalizumab was the most commonly prescribed therapy among Medicaid patients between 2015 and2024.
Eric R. Ramos +7 more
wiley +1 more source
New approaches to treating chronic obstructive pulmonary disease with Colla corii asini
Animal Models and Experimental Medicine, EarlyView.Colla corii asini improves chronic obstructive pulmonary disease (COPD) treatment through anti‐inflammatory, antioxidant, immune‐modulatory, and lung‐nourishing effects, addressing current therapeutic challenges via multitarget mechanisms. Abstract Chronic obstructive pulmonary disease (COPD) is one of the leading causes of death and disability ...
Wenchao Zhang +5 more
wiley +1 more source
College Students' Perceptions of Prescription and Non-Prescription Drug Use
, 2018 Lisa A. Gallagher
openalex +1 more source
Annals of Neurology, EarlyView.Objective The objective of this study was to compare the long‐term safety profiles of ocrelizumab and rituximab in persons with multiple sclerosis (MS). Methods Using retrospective data from the University of California (UC) Health System, we simulated a target clinical trial. The primary cohort from UC San Francisco (UCSF) and a validation cohort from
Gabriel Cerono +3 more
wiley +1 more source
Annals of Neurology, EarlyView.Objective Identifying modifiable factors influencing amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) risk is important for prevention. Blood biomarkers, particularly cholesterol, have been associated with neurodegenerative risk, but findings in ALS are inconsistent, and data on FTD are limited.
Christos V. Chalitsios +5 more
wiley +1 more source